FINWIRES · TerminalLIVE
FINWIRES

SHA:688266

4 stories mentioning SHA:688266Updated 12m ago

Every FINWIRES story that references SHA:688266, newest first.

Asia

Zelgen Biopharmaceuticals Gets Nod to Market Gecacitinib Hydrochloride Tablets as Alopecia Drug

Suzhou Zelgen Biopharmaceuticals (SHA:688266) obtained a drug registration certificate from China's National Medical Products Administration to allow its gecacitinib hydrochloride tablets to be marketed as a treatment for adult severe alopecia areata, according to a Shanghai bourse filing on Tuesday.The drug was also approved to be a treatment for intermediate- and high-risk myelofibrosis.

SHA:688266
Asia

Zelgen Biopharmaceuticals Presents Two Cancer Drugs in US Convention

Suzhou Zelgen Biopharmaceuticals (SHA:688266) presented two cancer drugs at the American Society of Clinical Oncology, according to a Shanghai bourse filing on Tuesday.The drugs presented were Nilvanstomig, which was developed as a treatment for hepatocellular carcinoma, and Alveltamig, a T-cell engager immunotherapy.Both drugs showed safety profiles during the clinical trials.

SHA:688266
Asia

China's Stocks Muted Over Fresh Blows Between US, Iran

China's shares were flat, leaning in negative territory, at the closing of the trading week as global sentiment slumped over the U.S. and Iran trading fire despite the ceasefire.The Shanghai Composite Index marginally slipped to cap Friday's trade at 4,179.95. The Shenzhen Component Index dropped 0.5%, or 78.09 points, to 15,563.80.U.S. President Donald Trump said the ceasefire is still in effect despite trading blows with Iran. Tehran claimed the U.S. forces targeted civilian areas, while the U.S. said its forces hit Iranian military facilities that attacked its warships in the Strait of Hormuz.In corporate news, Geo-Jade Petroleum (SHA:600759) dropped 5% as its controlling shareholder, Guangxi Zhenghe Industrial Group, faces bankruptcy.Suzhou Zelgen Biopharmaceuticals (SHA:688266) fell 3% despite the third phase trial for recombinant human thyrotropin alfa for injection reaching the primary endpoint in differentiated thyroid cancer patients without distant metastases.

Shanghai Composite^SZSESHA:600759SHA:688266
Asia

Zelgen Biopharmaceuticals' Thyroid Cancer Drug Meets Third Phase Goal; Shares Down 3%

Suzhou Zelgen Biopharmaceuticals' (SHA:688266) third phase trial for recombinant human thyrotropin alfa for Injection achieved the prespecified primary endpoint for radioactive iodine remnant ablation in differentiated thyroid cancer patients without distant metastases, the company said in a Friday filing with the Shanghai bourse.The study demonstrated non-inferior efficacy compared to conventional thyroid hormone withdrawal.The company is planning to submit the drug for a biologics license application for the above indication.Share of Suzhou Zelgen Biopharmaceuticals were down 3% in recent trade.

SHA:688266

Track with the FINWIRES app suite